Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastomaHolly Pacenta, Margaret E. Macy|Drug Design Development and Therapy|2018Cited by 53
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemiaSara Silbert, Marlie R. M. Provost, Marie Balsat et al.|Blood|2025Cited by 33
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task ForceHolly Pacenta, Theodore W. Laetsch, Wendy Allen‐Rhoades et al.|Journal of Clinical Medicine|2021Cited by 28
Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LSSara Silbert, Elad Jacoby, Cynthia Harrison et al.|Blood|2023Cited by 5
Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia; A Merged Analysis from the Prwcc and PHISPrakash Satwani, Liora M. Schultz, Karen Chao et al.|Blood|2023Cited by 1